Sab BiotherapeuticsSABS
13F holders, Q1 2025 (March 31)At the end of Q1 2025, 26 institutions reported holding Sab Biotherapeutics Inc. (SABS) in their 13F filings, up 1 from Q4 2024. 4 opened new positions and 3 sold out. The largest holders were BVF Inc. ($1.2M), Sessa Capital IM, L.P. ($624K) and Vanguard Group Inc. ($375K). 2 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Sab Biotherapeutics Inc.
- CUSIP
- 78397T202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $66K |
| Exits | 3 | $1.9M |
All 13F filers, Q4 2024 → Q1 2025: 81,299 shares bought and 504,846 shares sold, net −423,547 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 26 holders
| BVF Inc. | 0.05% | No change | 917,826 | $1.2M |
| Sessa Capital IM, L.P. | 0.03% | No change | 458,457 | $624K |
| Vanguard Group Inc. | 0.00% | Add +0.1% | 277,510 | $375K |
| HB Wealth Management, LLC | 0.00% | Add +10.9% | 263,200 | $358K |
| Geode Capital Management, LLC | 0.00% | Add +5.5% | 84,685 | $114K |
| Pathstone Holdings, LLC | 0.00% | No change | 50,650 | $69K |
| BlackRock, Inc. | 0.00% | Reduce -1.3% | 22,301 | $30K |
| Silver Oak Securities, Incorporated | 0.00% | New | 20,188 | $30K |
| NorthCoast Asset Management LLC | 0.00% | No change | 19,201 | $26K |
| First PREMIER Bank | 0.01% | No change | 18,986 | $26K |
| XTX Topco Ltd | 0.00% | New | 16,555 | $22K |
| Millennium Management | 0.00% | Reduce -44.4% | 16,351 | $22K |
| Kestra Advisory Services, LLC | 0.00% | No change | 11,930 | $16K |
| Northern Trust Corp. | 0.00% | No change | 11,387 | $15K |
| Renaissance Technologies | 0.00% | New | 10,030 | $14K |
| Osaic Holdings, Inc. | 0.00% | Reduce -2.0% | 4,947 | $7K |
| Sachetta, LLC | 0.00% | Add +4000.0% | 4,100 | $6K |
| Morgan Stanley | 0.00% | Reduce -25.0% | 449 | $610 |
| MAI Capital Management | 0.00% | Add +66.9% | 217 | $296 |
| GS Investments, Inc. | 0.00% | No change | 200 | $272 |
| JPMorgan Chase & Co. | 0.00% | Reduce -1.9% | 103 | $139 |
| UBS Group AG | 0.00% | Reduce -92.8% | 78 | $106 |
| Bank of America Corp. | 0.00% | Add +4.7% | 67 | $91 |
| Harbour Investments, Inc. | 0.00% | No change | 50 | $68 |
| SBI Securities Co., Ltd. | 0.00% | New | 50 | $68 |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -96.0% | 34 | $46 |
"% of holder's portfolio" is SABS's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. the manager owns.